Pharmacological inhibition of KIT activates MET signaling in gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GIST) are the most common adult sarcomas and the oncogenic driver is usually a KIT or PDGFRA mutation. While GIST are often initially sensitive to imatinib or other tyrosine kinase inhibitors, resistance generally develops necessitating backup strategies for therapy....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Res
Egile Nagusiak: Cohen, Noah A., Zeng, Shan, Seifert, Adrian M., Kim, Teresa S., Sorenson, Eric C., Greer, Jonathan B., Beckman, Michael J., Santamaria-Barria, Juan A., Crawley, Megan H., Green, Benjamin L., Rossi, Ferdinand, Besmer, Peter, Antonescu, Cristina R., DeMatteo, Ronald P.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4467991/
https://ncbi.nlm.nih.gov/pubmed/25836719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-2564
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak